Dott.ssa Gini Beatrice - University of California, San Diego
Feb 19, 2014 - Time:
Aula C lente didattica
Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor of adults. Comprehensive genomic analyses identified key GBM gene alterations and started to stratify patient subgroups that could potentially benefit from specific targeted therapies. Despite this extensive sub-classification, still targeted therapies in GBM have been modestly successful. In this talk I will present a major paradigm that could significantly challenge the efficacy of targeted therapeutic: the single cell cancer evolution. Using GBM patient derived cell models and tissues, resistance to targeted therapies was dynamically dissected at single cell level, identifying previously unrecognized molecular determinants. This work will translate into potentially more successful protocol of GBM treatment.